Related Experiment Videos
Targeting TDO in cancer immunotherapy
Cheng-Peng Yu1, Yun-Lei Song2, Zheng-Ming Zhu3
1The Second Clinic Medical College, School of Medicine, Nanchang University, Nanchang, China.
Medical Oncology (Northwood, London, England)
|March 31, 2017
Summary
Tryptophan-2,3-dioxygenase (TDO) impacts cancer immunity by altering tryptophan metabolism. Inhibiting TDO shows promise as a novel cancer therapy by modulating the anti-tumor immune response.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Tryptophan-2,3-dioxygenase (TDO) is a key enzyme in the kynurenine pathway, regulating tryptophan metabolism.
- TDO upregulation decreases tryptophan levels and increases kynurenine, impacting T cell proliferation and anti-tumor immunity.
Purpose of the Study:
- To review the biological features and regulatory mechanisms of TDO.
- To elucidate the role of TDO in anti-tumor immune responses across various cancers.
- To discuss the potential of TDO inhibitors as cancer therapeutics.
Main Methods:
- Literature review of TDO's biological functions and regulatory mechanisms.
- Analysis of TDO's involvement in anti-tumor immunity in different cancer types.
- Exploration of TDO inhibitors for cancer treatment development.
Main Results:
- TDO plays a significant role in modulating the tumor microenvironment and immune evasion.
- Accumulation of kynurenine pathway metabolites affects T cell function and anti-tumor responses.
- TDO is identified as a promising therapeutic target for cancer immunotherapy.
Conclusions:
- TDO is a critical regulator of the anti-tumor immune response and a viable therapeutic target.
- Further research into TDO inhibitors could lead to novel strategies for cancer treatment.
- Understanding TDO's role is crucial for developing effective cancer immunotherapies.